Shares in Cambridge biopharma company Arecor Therapeutics hit a 52-week low at 54.75p on Friday before recovering to close at ...

Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding ...

Arecor Therapeutics has signed an exclusive licensing agreement for AT351, its ready-to-dilute (RTD) liquid drug product, ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

The Footsie has now shed more than 2% this month and 4% since its peak in May. But it remains up about 5% this year and has ...

Stock markets look set to end the year with a whimper rather than a bang. On London’s last full day of trading of 2024 (the exchange closes at 12.30pm today) the FTSE 100 was down 0.35 per ...

(Sharecast News) - Arecor Therapeutics announced the signing of an exclusive licensing agreement for AT351, a ready-to-dilute (RTD) liquid formulation of a widely-used critical care therapy ...

(Alliance News) - London's FTSE 100 is to open lower on Monday, with hawkish Federal Reserve rate expectations keeping a lid on equity market enthusiasm as the year draws to an end. US stocks slid on ...

Arecor Therapeutics has entered into an exclusive licensing agreement for AT351, a ready-to-dilute liquid formulation of a critical care therapy, with a major chemicals marketing company’s ...

Arecor receives an upfront milestone payment and is eligible for development, regulatory and commercial milestones, and royalties on global sales - Licensee gains exclusive rights to further ...

Licensee gains exclusive rights to further develop and commercialise AT351 -AT351 has potential to be the first ...